论文部分内容阅读
目的观察地西他滨联合化疗治疗难治复发急性髓系白血病(AML)的治疗效果。方法选取收治的急性髓系白血病患者42例,根据患者自身情况选用不同的治疗方案。结果 42例AML患者中病情得到不同程度缓解40例,治疗无效2例。所有患者的生命期得到延长,随访截止时仍有2例患者健在。所有患者血液学毒性不良反应较为严重,其余不良反应较轻,患者可以耐受。结论地西他滨联合化疗治疗作为一种新型治疗方案对于难治复发急性髓细胞白血病有一定效果,可以延长患者的生存期并减少患者的不良反应的发生。
Objective To observe the therapeutic effect of decitabine combined with chemotherapy on refractory recurrent acute myeloid leukemia (AML). Methods Forty-two patients with acute myeloid leukemia were selected, and different treatment regimens were selected according to their own circumstances. Results In 42 AML patients, 40 cases were relieved to varying degrees and 2 cases were ineffective. The life span of all patients was prolonged, and 2 patients remained alive at the end of the follow-up period. All patients with hematological toxicity is more serious adverse reactions, the remaining adverse reactions, patients can tolerate. Conclusion Decitabine combined with chemotherapy has a certain effect on refractory recurrent acute myeloid leukemia as a new treatment plan, which can prolong the survival of patients and reduce the incidence of adverse reactions in patients.